Citations

Institution: Mayo Clinic Clear

Showing 10 of 108083 citations.

Bridging the clinical gap: Confidence informed IDH prediction in brain gliomas using MRI and deep learning
Yogananda, Chandan Ganesh Bangalore , Truong, Nghi Cong Dung , Wagner, Benjamin , Bowerman, Jason, Reddy, Divya D. , Holcomb, James M. , Saadat, Niloufar , Hatanpaa, Kimmo J. , Lee, Matthew , Bruce, Richard J. , Madhuranthakam, Ananth J. , Bangalore Yogananda, Chandan Ganesh , Jain, Rajan , Xi, Yin , Patel, Toral , Fei, Baowei , Jain, Rajan , Pinho, Marco C. , Maldjian, Joseph A.

Neuro-Oncology Advances | August 20, 2025 | Volume: 7 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdaf142 | PMID 40842645 Get It

Abstract Background The isocitrate dehydrogenase (IDH) mutation status is a key molecular marker in diagnosing and treating brain tumors. Currently, it is determined via invasive tissue biopsy. Recent advances in deep learning (DL) have offered promising non-invasive alternatives for determining IDH status. However, their clinical translation is hindered by a significant gap between DL predictions and their clinical applicability. The limited transparency of many DL-networks and inadequate evaluation metrics hinders trust and adoption, as clinicians require clear and validated insights for determining IDH status. These challenges highlight the need for robust validation and measures of predictive reliability to make DL-predictions clinically actionable. Methods We developed a unique approach for non-invasive prediction of IDH status using MRI. We combine a voxel-wise-segmentation network(MC-net) with Bayesian logistic regression (BLR) to provide an IDH status and estimate confidence scores. We utilized a comprehensive dataset of 2,481 glioma cases from eight institutions. Results Our framework(MC-net + BLR) demonstrated robust performance achieving 96.4% and 95.1% classification accuracies on diverse databases, with an AUC of 0.98. The BLR was implemented exclusively on held-out test data, ensuring that the derived confidence scores are independent of the training or validation phases. The derived confidence scores showed a low Brier score of 0.0125, highlighting its superior calibration and uncertainty quantification. Conclusion The developed framework provides an IDH status and a confidence score, offering clinicians an additional layer of assurance in prediction reliability. It bridges the gap between high-performing DL models and their clinical applicability by addressing the challenges in prediction reliability. Our framework is a significant advancement in non-invasive determination of IDH-status and confidence-informed therapeutic decision-making in neuro-oncology.
Extracorporeal Membrane Oxygen Assisted Intubation for Complex Airways
Bhalerao, R A, Hinni, Michael L., Bhalerao, Ritu V , Sell‐Dottin, Kristen , Chang, Brent A.

Ear, Nose & Throat Journal | August 20, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/01455613251368709 | PMID 40832957 Get It

Objective: Airway management in patients with severely-narrowed tracheal lumens presents significant challenges, especially when traditional intubation methods are not feasible. In such cases, failed intubation attempts can worsen airway compromise and cause life-threatening complications. Extracorporeal membrane oxygenation (ECMO) offers an alternative approach to ensure oxygenation and ventilation during complex airway surgeries. The objective of this study was to assess the safety and feasibility of using venovenous ECMO to ensure oxygenation before attempting intubation in patients with severely-narrowed tracheal lumens undergoing head and neck surgery. Methods: This is a retrospective case series of 3 adult patients who underwent venovenous ECMO-assisted intubation for head and neck surgeries at a single institution between 2010 and 2023. The primary outcome was the successful establishment of an airway and the avoidance of respiratory failure during the surgical procedure. Results: All 3 patients successfully underwent ECMO-assisted intubation. None of the patients experienced major complications directly attributable to ECMO, and all were extubated within 24 hours postoperatively. Conclusions: Venovenous ECMO provides an effective strategy for managing difficult airways in patients with severely-narrowed tracheas, enabling safe anesthesia induction. This technique may be crucial in preventing complications associated with traditional airway management methods.
Reply to “Letter to Editor by Dr. Steckner Regarding ‘Induction of Extremely Severe Nausea via Vestibular Activation on a 7 Tesla MRI Scanner’ by Fagan et al.”
Fagan, Andrew , Fagan, Andrew J

Journal of Magnetic Resonance Imaging | August 20, 2025 | Volume: 62 | Issue: 4 | Pages: 1234-1234

10.1002/jmri.70085 | PMID 40832859 Get It

Dysphagia Is Associated with Incident Non‐Motor Symptoms in Parkinson's Disease
Rehman, Muhammad Abdul , Savica, Rodolfo , Varma, Revati , Bailey, Kent R. , Bharucha, Adil E. , Abdul Rehman, Muhammad , Bharucha, A E , Vierkant, Robert A.

Movement Disorders Clinical Practice | August 20, 2025 | Volume: 12 | Issue: 11 | Pages: 1909-1924

10.1002/mdc3.70297 | PMID 40832733 Get It

Abstract Background Up to 80% of persons with Parkinson's disease (PwPD) have dysphagia. However, existing studies are based on small cohorts and the relationship between dysphagia and other motor and nonmotor symptoms (NMS) remains incompletely understood. Objectives To evaluate the relationship between motor and NMS in PwPD with vs without dysphagia. Methods Among 20,365 PwPD in the Michael J. Fox Foundation database who completed ≥2 NMS surveys, 12,678 (62%) reported dysphagia on ≥1 survey. We examined associations between dysphagia and: (1) self‐reported motor symptoms (UPDRS Part II), other NMS, quality of life (QoL), comorbidity score, depression, and daily activities at baseline; and (2) development of new NMS. Results Compared to PwPD without dysphagia, those with dysphagia were more likely to have had PD for >5 years, more severe motor and NMS, higher comorbidity scores, and a greater impairment in daily activities ( P < 0.001). The prevalence of dysphagia increased with the severity of motor symptoms at the index survey ( P < 0.001). At baseline, all NMS were significantly associated with dysphagia. Compared to PwPD who did not have dysphagia, PwPD with dysphagia were at increased risk of developing every NMS, even after adjusting for ages at PD diagnosis and index survey, sex, cognitive impairment, UPDRS, NMS and comorbidity scores. For most NMS, the risk of progression was greater in those with cognitive impairment or elevated NMS scores. Conclusions Dysphagia in PwPD is associated with more severe motor and non‐motor symptoms, reduced QoL, and an increased risk of future NMS.
Natural Openings in the Paraneurium and Epineurium of the Human Sciatic Nerve and Their Relationship to the Entry and Exit of Blood Vessels. A Microanatomical Study
Ruiter, Godard C. W. de , Spinner, Robert J. , Sala‐Blanch, Xavier , Reina, Miguel Ángel , de Ruiter, Godard C W , Reina, Miguel Angel , Sala-Blanch, Xavier

Clinical Anatomy | August 20, 2025 | Volume: 39 | Issue: 4 | Pages: 461-469

10.1002/ca.70021 | PMID 40832724 Get It

ABSTRACT The microvasculature of peripheral nerve not only is important for the understanding of the development of compression syndromes, but it plays a critical role in the evolution of other nerve pathologies, including, for example, the distribution of intraneural ganglion cysts and lymphoma. We investigated the anatomical course of vessels around the human sciatic nerve and its bifurcation in eight human cadavers. Specifically, the presence of fenestrations on the epineurium and paraneurium's thickness in relation to the intraneural vessels was investigated. The sciatic, tibial, peroneal and sural nerves at the level of the bifurcation are surrounded by different layers, including the epineurium and paraneurial layers. Multiple fenestrations were observed in all membranes surrounding these nerves, which formed openings for the transfer of adipocytes and vessels from one compartment to the neighboring one. The openings were relatively large compared to the size of the vessels. In conclusion, vessels always travel through a natural opening in the paraneurial and epineurium. These vessels are important connections between the extrinsic and intrinsic nerve vasculature. In addition, the fenestration provides an important anatomical explanation for the possibility of transfer of anesthetic agents or different nerve pathologies, including intraneural ganglion cyst and tumors.
Dehydroepiandrosterone Sulfate in Diagnosing Mild Autonomous Cortisol Secretion and Adrenal Insufficiency
Saini, Jasmine , Salama, Bahaa , Yu, Kai , Chacko, Shireen R , Han, Ashley J , Villavicencio, Camila , Villavicencio Torres, Camila , Murad, Mohammad Hassan, Bancos, Irina , Saini, Jasmine , Murad, M. Hassan , Bancos, Irina

Journal of the Endocrine Society | August 20, 2025 | Volume: 9 | Issue: 9 | Pages: No page available

10.1210/jendso/bvaf136 | PMID 40909019 Get It

Abstract Context Data on diagnostic accuracy of dehydroepiandrosterone sulfate (DHEA-S) for mild autonomous cortisol secretion (MACS) and adrenal insufficiency (AI) are discrepant. Objective We conducted a systematic review and meta-analysis of published studies assessing the accuracy of DHEA-S in diagnosing MACS or AI. Methods From inception to January 8, 2024, we searched databases for original studies of at least 20 participants with MACS or AI. MACS was defined as postdexamethasone cortisol greater than 1.8 mcg/dL or postsurgical hypocortisolism. AI was defined by abnormal dynamic testing. QUADAS-2 was used to assess the risk of bias. Bivariate random effects meta-analysis was used to generate pooled diagnostic accuracy estimates. Results Seven studies on DHEA-S accuracy in diagnosing MACS (574 patients with MACS, 830 referent individuals), and 2 studies on DHEA-S accuracy in diagnosing AI (52 patients with AI, 59 referent individuals) were included. A meta-analysis of studies using DHEA-S cutoff between 60 and 70 mcg/dL to diagnose MACS demonstrated a sensitivity of 82% (95% CI, 64%-93%) and a specificity of 82% (95% CI, 74%-88%). In the 2 studies evaluating DHEA-S in diagnosing AI, the reference standard was a 1-mcg cosyntropin stimulation test. The sensitivity of DHEA-S for diagnosing AI ranged from 70.3% to 86.7%, and the specificity was 87.1%. Most studies were at a moderate risk of bias. Conclusion Based on limited heterogeneous evidence, measurement of DHEA-S provides additional value in diagnosing MACS, as well as AI.
Early Thrombolysis and Outcomes in Central Retinal Artery Occlusion: An Individual Participant Data Meta-Analysis
Xie, Jim Shenchu , Chaban, Yuri V. , Lusterio, Adrien , Kaur, Hargun , Motekalem, Yasmin, Zeraatkar, Dena , Althaus, Katharina , Malbin, Brett , Nolte, Christian H. , Pettersen, Jacqueline A. , Woo, Se Joon , Chen, Celia S. , Khrlobyan, Manya, Sangha, Navdeep , Jurado, Elena Ardila, Mattle, Heinrich P. , Nedelmann, Max, Spitzer, Martin S. , Poli, Sven , Hametner, Christian , Baumgartner, Philipp , Kook, Lucas , Dumitrascu, Oana M. , Margolin, Edward , Xie, Jim S , Zaslavsky, Kirill , Chaban, Yuri V , Lusterio, Adrien , Popovic, Marko M , Althaus, Katharina , Malbin, Brett , Nolte, Christian H , Scheitz, Jan F , Pettersen, Jacqueline A , Leker, Ronen R , Kim, Joonhyung , Woo, Se Joon , Chen, Celia , Feltgen, Nicolas , Sangha, Navdeep , Arnold, Marcel , Mattle, Heinrich , Heldner, Mirjam R , Cordonnier, Charlotte , Poli, Sven , Hametner, Christian , Baumgartner, Philipp , Wegener, Susanne , Kook, Lucas , Shahjouei, Shima , Dumitrascu, Oana M , Margolin, Edward M , Heldner, Mirjam R. , Shahjouei, Shima , Michel, Patrik

Stroke | August 20, 2025 | Volume: 56 | Issue: 11 | Pages: 3175-3186

10.1161/strokeaha.124.049955 | PMID 40832714 Get It

BACKGROUND: This individual participant data meta-analysis aimed to determine whether time to treatment influences the effect of intraarterial thrombolysis (IAT), intravenous thrombolysis, and conservative standard therapy on visual outcomes in nonarteritic central retinal artery occlusion. METHODS: We searched MEDLINE, CENTRAL, and Embase up to June 2023 for studies reporting treatment modality and peri-treatment best-corrected visual acuity (BCVA) for ≥5 participants, excluding patients with nonsevere vision loss (BCVA <1.0 logarithm of the minimum angle of resolution [logMAR]) or treated after 24 hours of symptom onset. The primary outcome was recovery from severe vision loss (final BCVA <1.0 logMAR). We used mixed-effect models and local polynomial regression to investigate nonlinear relationships between time to treatment and recovery from severe vision loss. RESULTS: Of 4074 screened studies, individual participant data were sought from 52, with 35 contributing individual participant data for 1038 participants. In total, 783 patients met inclusion criteria (age, 64.8±13.3 years; 35.5% female; baseline BCVA, 2.3±0.5 logMAR). For every hour decrease in time to treatment, thrombolysis was associated with greater improvement in BCVA (intraarterial, 0.02 logMAR [95% CI, 0–0.04]; intravenous, 0.04 logMAR [95% CI, 0.00–0.07]) than conservative standard therapy (0.01 logMAR [95% CI, 0–0.02]). A nonlinear relationship was detected for intraarterial thrombolysis with a changepoint at 8 hours (95% CI, 6.7–9.4). Thrombolysis was associated with increased recovery from severe vision loss compared with conservative standard therapy (intraarterial within 6 hours: odds ratio, 2.72 [95% CI, 1.02–7.28], 27.2% versus 12.0%; intravenous within 4.5 hours: odds ratio, 3.32 [95% CI, 1.24–8.92], 28.8% versus 11.1%). Findings were consistent in subgroup analysis restricted to patients receiving recombinant tissue-type plasminogen activator. Monte-Carlo simulations showed that a randomized controlled trial would require 95 participants per group to achieve 80% power to detect an odds ratio of 3.0 for recovery from severe vision loss. CONCLUSIONS: Early intervention in nonarteritic central retinal artery occlusion is associated with improvement in visual recovery, with intraarterial thrombolysis and intravenous thrombolysis outperforming nonthrombolytic treatments. These findings warrant confirmation in sufficiently powered randomized controlled trials.
The impact of peri-operative chemotherapy on the Outcomes of Patients with non-metastatic biliary tract cancer
Alhayek, Bakr , Malone, Xiaowei , Alhayek, Bakr , Baidoun, Firas , Moustafa, Muhamad Alhaj , Abdel-Rahman, Omar Mohammed

No container title available | August 20, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-7285305/v1 Get It

Abstract Introduction Biliary-tract cancers, including intra- and extra-hepatic cholangiocarcinoma and gallbladder carcinoma, are uncommon but highly lethal. They represent roughly 2–3 % of new cancer diagnoses yet contribute about 5 % of cancer-related deaths. Complete surgical resection remains the foundation of curative treatment, whereas the value of peri-operative chemotherapy continues to be debated. Materials and Methods The National Cancer Database (NCDB) was queried for patients diagnosed with non- metastatic biliary tract cancer at age 18 or older between 2004 and 2019. After excluding patients with unknown timing of surgery and chemotherapy, patients who died within 90 days of the most definitive primary site surgery, and patients lost to follow-up, we split the cohort into three groups according to the clinical stage (stage I-III). Then, we evaluated the overall survival (OS) between the different treatment modalities (surgery only, chemotherapy only, adjuvant chemotherapy following surgery, and neoadjuvant chemotherapy followed by surgery) in each group. We studied the OS using Kaplan-Meier estimates and multivariate Cox regression analyses to evaluate factors associated with OS. Results A total of 35,260 patients with non-metastatic biliary tract cancers were included in the analysis, of which 50.4% were females, 83% Caucasians, and 9.5% African Americans. The median age at diagnosis was 70 (range 18-90). 14,757 (41.9%) were stage I, 12,472 (35.4%) stage II, and 8,031 (22.8%) stage III. 7,286 (20.7%) had surgical resection only, 8,144 (23.1%) had chemotherapy only, 6,964 (19.7%) had surgical resection with perioperative chemotherapy, and 12,866 (36.5%) did not receive any treatment. We compared survival between different treatment modalities based on clinical stage. In stage I, patients treated with surgery alone exhibited superior median OS compared with those receiving adjuvant chemotherapy (65.7 vs 50.4 months, P < 0.001). Median OS after neoadjuvant chemotherapy was numerically higher than surgery alone (79.8 vs 65.7 months); however, this difference was not statistically significant (P = 0.63). Whereas in stage II, patients who were treated with adjuvant and neoadjuvant chemotherapy had better mOS compared to those treated with surgery only (33.9 and 40.3 vs 29.9 months with P<0.001 and P=0.005, respectively). The same trend was seen in stage III, patients who were treated with adjuvant and those treated with neoadjuvant chemotherapy had better mOS compared to surgery only (22.6 and 41.5 vs 19.5 months, respectively, with P<0.001 for all). In multivariate analysis, adjuvant and neoadjuvant chemotherapy did not affect the OS in all stages, except in stage III, where neoadjuvant chemotherapy was associated with better OS (HR 0.646, 95% CI 0.530-0.786; P<0.001). Conclusion Adjuvant and neoadjuvant chemotherapy do not seem to have a survival benefit in early-stage (stage I and II) biliary tract cancers, whereas neoadjuvant chemotherapy tends to improve OS in stage III.
Artifacts in Urodynamic Studies: A Narrative Review
Pourghazi, Farzad , Linder, Brian J. , Linder, Brian J , Alizad, Azra , Fatemi, Mostafa

Neurourology and Urodynamics | August 20, 2025 | Volume: 44 | Issue: 8 | Pages: 1583-1592

10.1002/nau.70128 | PMID 40831019 Get It

ABSTRACT Background Urodynamic studies (UDS) are integral to the evaluation and management of lower urinary tract dysfunction. However, artifacts are frequently encountered, affecting both clinical interpretation and research reliability. Objective This expert narrative review examines the prevalence, classification, and clinical relevance of artifacts encountered during UDS, based on findings from the existing literature. Methods A focused literature review was conducted, analyzing studies that reported data on the sources and impact of UDS artifacts, particularly from the patient perspective. Emphasis was placed on identifying both technical and patient‐related contributors to artifact generation. Results Artifacts are common in UDS despite adherence to Good Urodynamic Practices recommended by the International Continence Society. Technical artifacts may stem from equipment‐related issues such as calibration errors, catheter displacement, and device variability. Patient‐related artifacts can arise from physical movement or test‐induced detrusor overactivity. These artifacts may lead to misinterpretation, misdiagnosis, and inappropriate interventions in clinical practice. Furthermore, they may affect the validity of research findings related to diagnostic tools for lower urinary tract symptoms. Conclusion Identifying and addressing UDS artifacts during the procedure or in post‐test interpretation is critical for accurate clinical decision‐making and reliable research outcomes. Efforts to minimize artifacts should be prioritized to improve the quality and utility of UDS.
Cerebellum mitochondrial DNA copy number is increased in Parkinson’s disease
Beglarian, Talia , Tyrpak, David R. , MacKay, J. Andrew , Scholz, Sonja W. , Albert, Marilyn S. , Dawson, Ted M. , Troncoso, Juan C. , Hernandez, Dena G., Cookson, Mark R , Singleton, Andrew B., Beach, Thomas G., Hjelm, Brooke E. , MacKay, John Andrew , Scholz, Sonja W , Dawson, Ted M , Cookson, Mark , Adler, C H , Serrano, Geidy E , Hjelm, Brooke E , Gibbs, J. Raphael , Traynor, Bryan J , Rosenthal, Liana S. , Adler, Charles H. , Serrano, Geidy E. , Singleton, Andrew B., Beach, Thomas G.

Brain Communications | August 20, 2025 | Volume: 7 | Issue: 4 | Pages: No page available

10.1093/braincomms/fcaf296 | PMID 40873892 Get It

Abstract Bioinformatics methods can be used to quantify mitochondrial DNA copy number from whole genome sequencing (WGS) data. We evaluated mitochondrial DNA copy number from human brain-derived WGS data using the fastMitoCalc tool. 341 Parkinson’s Disease cerebellum samples were compared with 74 age-matched controls from the North American Brain Expression Consortium. Parkinson’s Disease cerebellum had significantly higher mitochondrial DNA copy number compared with controls (P = 4.15e–7), and this effect was reproducible in four of five brain banks when analysis was restricted to each resource that contributed Parkinson’s Disease samples to this genetic dataset. Follow-on analyses of 128 Parkinson’s Disease cerebellum samples and 33 controls that had paired neuropathology data and clinical scores demonstrated a significant increase in mitochondrial DNA copy number with Unified Staging System for Lewy Body disorders stages and Unified Parkinson’s Disease Rating Scale (off meds) motor scores. Analysis of Lewy Body scores from ten brain regions showed cerebellum mitochondrial DNA copy number increased upon pathological infestation of α-synuclein aggregates in the brainstem and limbic system but did not increase after late-stage neocortical involvement. This genetics dataset supports previous observations of cerebellum activation in Parkinson’s Disease and suggests mitochondrial DNA copy number may increase to support this regional activation as a compensatory mechanism to pathology or motor symptoms.